Status:
COMPLETED
Iscar for Supplemental Care in Stage IV Lung Cancer
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving convent...
Detailed Description
See Brief Summary
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Stage IV NSCLC patients who receive standard chemotherapy
- Exclusion criteria:
- Known allergy to Viscum Album L.
- Concomitant use of other mistletoe products
- Concomitant use of mushroom glucan and proteoglycan extracts
- Concomitant use of thymus extract products
- Inability to self-report quality of life utilizing assessment tools
- Ongoing steroid or ACTH therapy
- Co-morbid immunocompromised state
- Pregnancy
- Participation in other clinical trials
Exclusion
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
End Date :
February 1 2004
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00079794
Start Date
September 1 2001
End Date
February 1 2004
Last Update
January 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107